Founded in 1970, Hengrui Medicine is the largest publicly listed and a leading biopharma based in China with 20,000+ employees devoted to empowering healthier lives through research. With approximately $2.5 billion in revenue, Hengrui has 4 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular diseases.